MetaVia (MTVA) Competitors $0.74 +0.00 (+0.64%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock MTVA vs. ABOS, JSPR, CLSD, IVVD, VHAQ, ACHL, ALTS, INCR, ASRT, and RENBShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Acumen Pharmaceuticals (ABOS), Jasper Therapeutics (JSPR), Clearside Biomedical (CLSD), Invivyd (IVVD), Viveon Health Acquisition (VHAQ), Achilles Therapeutics (ACHL), Janone (ALTS), InterCure (INCR), Assertio (ASRT), and Renovaro (RENB). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Acumen Pharmaceuticals Jasper Therapeutics Clearside Biomedical Invivyd Viveon Health Acquisition Achilles Therapeutics Janone InterCure Assertio Renovaro Acumen Pharmaceuticals (NASDAQ:ABOS) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk. Which has more risk and volatility, ABOS or MTVA? Acumen Pharmaceuticals has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500. Comparatively, MetaVia has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Does the MarketBeat Community believe in ABOS or MTVA? Acumen Pharmaceuticals received 24 more outperform votes than MetaVia when rated by MarketBeat users. However, 100.00% of users gave MetaVia an outperform vote while only 72.97% of users gave Acumen Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAcumen PharmaceuticalsOutperform Votes2772.97% Underperform Votes1027.03% MetaViaOutperform Votes3100.00% Underperform VotesNo Votes Is ABOS or MTVA more profitable? Acumen Pharmaceuticals' return on equity of -32.99% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -32.99% -27.99% MetaVia N/A -189.12%-122.31% Do analysts prefer ABOS or MTVA? Acumen Pharmaceuticals currently has a consensus target price of $7.33, suggesting a potential upside of 671.12%. MetaVia has a consensus target price of $12.00, suggesting a potential upside of 1,658.50%. Given MetaVia's higher probable upside, analysts plainly believe MetaVia is more favorable than Acumen Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33MetaVia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ABOS or MTVA? In the previous week, MetaVia had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 2 mentions for MetaVia and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.68 beat MetaVia's score of 0.62 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MetaVia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ABOS or MTVA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$52.37M-$1.71-0.56MetaViaN/AN/A-$12.47MN/AN/A Do insiders and institutionals have more ownership in ABOS or MTVA? 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 1.1% of MetaVia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryAcumen Pharmaceuticals beats MetaVia on 9 of the 14 factors compared between the two stocks. Remove Ads Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.91M$6.40B$5.27B$7.32BDividend YieldN/A3.24%5.11%4.31%P/E RatioN/A6.7621.6617.68Price / SalesN/A224.20377.2292.80Price / CashN/A65.6738.1534.64Price / Book0.205.796.363.94Net Income-$12.47M$142.01M$3.20B$247.45M7 Day Performance-50.19%6.52%4.07%3.32%1 Month Performance-57.08%-14.92%-10.26%-8.51%1 Year PerformanceN/A-10.33%10.36%0.66% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia2.0242 of 5 stars$0.74+0.6%$12.00+1,523.8%N/A$6.40MN/A0.008Analyst ForecastGap DownABOSAcumen Pharmaceuticals3.2433 of 5 stars$1.05-4.5%$7.33+598.4%-72.0%$63.60MN/A-0.7620Positive NewsJSPRJasper Therapeutics1.9455 of 5 stars$4.23+0.7%$62.50+1,377.5%-83.8%$63.54MN/A-0.8920Positive NewsGap UpCLSDClearside Biomedical2.8761 of 5 stars$0.82+2.7%$5.25+538.8%-24.4%$63.51M$1.66M-1.8330Short Interest ↓IVVDInvivyd2.5518 of 5 stars$0.51-2.1%$7.52+1,362.4%-82.5%$62.99M$25.38M-0.26100Short Interest ↑Gap UpVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250ALTSJanoneN/A$3.77-2.1%N/AN/A$60.62M$12.53M0.00170Short Interest ↑INCRInterCure0.5392 of 5 stars$1.33+3.5%N/A-42.4%$60.38M$272.67M0.00350Short Interest ↑News CoverageASRTAssertio2.1523 of 5 stars$0.63+1.2%$2.75+336.9%-21.9%$60.28M$124.96M-0.8620Analyst UpgradeNews CoveragePositive NewsRENBRenovaro0.5533 of 5 stars$0.37+4.2%N/A-85.1%$59.30MN/A-0.4020 Remove Ads Related Companies and Tools Related Companies ABOS Alternatives JSPR Alternatives CLSD Alternatives IVVD Alternatives VHAQ Alternatives ACHL Alternatives ALTS Alternatives INCR Alternatives ASRT Alternatives RENB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTVA Stock Free MTVA Stock Alerts